Allison Transmission is Buy-rated, with near-term earnings risk but strong medium-term demand signals in North America ...

Allison Transmission stock is a Buy after its $2.7B Dana deal, boosting diversification, $120M synergies, and 2026 EBITDA ...

Plus: SpaceX has officially delivered the largest IPO in history. This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of ...

The next step in the youth quest is a technology called chemical reprogramming. The outspoken longevity scientist David Sinclair has been predicting that one day, you’ll go to the doctor and get a ...

Test time has arrived: the first person has been treated in a highly anticipated gene-therapy trial that aims to coax aged cells to take on a younger identity. The clinical trial is testing an ...

Background SIRT6 acts as a tumour suppressor in multiple cancers by regulating glucose and lipid metabolism, but its role in intrahepatic cholangiocarcinoma (ICC) remains unclear. Objective We ...

In oncology, the manipulation of metabolic processes within tumors has surfaced as a pivotal strategy for influencing cancer progression and therapy resistance. Tumor cells often undergo metabolic ...